Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 for all).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

European Journal of Heart Failure

NOVEMBER 29, 2023

ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

Circulation

SEPTEMBER 2, 2024

Circulation, Volume 150, Issue 10 , Page e224-e225, September 3, 2024.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Quality of Life Article Heart Failure 45

Heart BMJ

FEBRUARY 12, 2024

Learning objectives To understand the importance of exercise and physical activity in the general management and well-being of people with heart failure (HF). To be familiar with the specific considerations of exercise training prescription in specific HF population groups including HF with preserved ejection fraction.

Exercise 40

Exercise Heart Failure Preserved Ejection Fraction Pharmacology 40

The British Journal of Cardiology

AUGUST 21, 2024

Digoxin has been used in the management of chronic heart failure (HF) and atrial fibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.

Atrial Fibrillation 52

Atrial Fibrillation Heart Failure Preserved Ejection Fraction Quality of Life 52

DAIC

APRIL 22, 2024

RELIEVE-HF failed to meet its primary efficacy endpoint and did not reduce heart failure events or improve quality of life in heart failure patients with a preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 105

Preserved Ejection Fraction Quality of Life Heart Failure Pacemaker 105

The American Journal of Cardiology

APRIL 15, 2024

Publication date: Available online 13 April 2024 Source: The American Journal of Cardiology Author(s): Syed Imran Ahmed, Jonathan Kenyon, Hayley E. Billingsley, Hannah Salmons, Natalie J. Bohmke, Roshanak Markley, Antonio Abbate, Danielle L. Kirkman, Youngdeok Kim, Salvatore Carbone

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Heart Failure 40

European Journal of Heart Failure

DECEMBER 20, 2023

Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF).

Quality of Life 40

Quality of Life Preserved Ejection Fraction Pacemaker Heart Failure 40

DAIC

APRIL 9, 2024

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The study was funded by Imbria Pharmaceuticals, developer of ninerafaxstat.

Cardiomyopathy 52

Cardiomyopathy Quality of Life Preserved Ejection Fraction Chest Pain 52

HeartRhythm

APRIL 30, 2024

Introduction: The PACE HFpEF trial is a prospective, single-center, randomized multiple crossover study investigating the effects of pacing modality and accelerated pacing on quality of life, NT-proBNP, and functional capacity in patients with heart failure with preserved ejection fraction (HFpEF) without pacing indication.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Quality of Life Physiology 40

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 98

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 98

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

DAIC

MARCH 29, 2024

The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. HFpEF is HF with preserved ejection fraction in which pressure builds up in the heart and lungs due to a stiffened left ventricle.

Preserved Ejection Fraction 111

Preserved Ejection Fraction Heart Failure Quality of Life Hospital 111